Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 156 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Primary Open - Angle Glaucoma (POAG) Clear all

Conditions: Primary Open-angle Glaucoma
Interventions: iStent; Device
Lead sponsor: Glaukos Corporation; Industry
Eligibility: Not listed
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 18
States / cities: Chico, California • Huntington Beach, California • Napa, California + 15 more

Conditions: Glaucoma
Interventions: Observation only; Other
Lead sponsor: Peregrine Ophthalmic; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Goose Creek, South Carolina

Conditions: Glaucoma, Ocular Hypertension, Eye Disease
Interventions: AMA0076, Placebo; Drug
Lead sponsor: Amakem, NV; Industry
Eligibility: 30 Years to 85 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 9
States / cities: Artesia, California • Inglewood, California • Petaluma, California + 6 more

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: Voyager DSLT; Device
Lead sponsor: The Eye Institute of West Florida; Other
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Largo, Florida

Conditions: Primary Open Angle Glaucoma, Glaucoma, Primary Open Angle Glaucoma or Ocular Hypertension
Interventions: Direct Selective Laser Trabuloplasty; Device
Lead sponsor: Brian Shafer; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2026
U.S. locations: 1
States / cities: Plymouth Meeting, Pennsylvania

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Brinzolamide/brimonidine ophthalmic suspension, Simbrinza 0.2%/1% Ophthalmic Suspension; Drug
Lead sponsor: Padagis LLC; Industry
Eligibility: 18 Years and older
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: ATS907; Drug
Lead sponsor: Altheos, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Artesia, California

Conditions: Primary Open Angle Glaucoma
Interventions: Cataract surgery combined with ab-interno canaloplasty utililzing the iTrack Advance canaloplasty device, Cataract surgery; Device · Procedure
Lead sponsor: Nova Eye, Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Glaucoma
Interventions: Not listed
Lead sponsor: Wills Eye; Other
Eligibility: 40 Years to 80 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Primary Open Angle Glaucoma (POAG), Primary Open Angle Glaucoma of Both Eyes, Primary Open-Angle Glaucoma, Unspecified Eye, Ocular Hypertension (OHT)
Interventions: Experimental: QLS-111 ophthalmic solution, (0.015%), Experimental: QLS-111 ophthalmic solution, (0.03%), Experimental: QLS-111 ophthalmic solution, (0.075%), QLS-111 ophthalmic vehicle solution; Drug · Other
Lead sponsor: Qlaris Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Roswell, Georgia

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: DE-117 Low Dose ophthalmic solution, DE-117 Low/Middle Dose ophthalmic solution, DE-117 Middle Dose ophthalmic solution, DE-117 Middle/High Dose ophthalmic solution, DE-117 High Dose ophthalmic solution, latanoprost ophthalmic solution 0.005%; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 14
States / cities: Chandler, Arizona • Artesia, California • Glendale, California + 11 more

Conditions: Primary Open Angle Glaucoma
Interventions: dietary supplement with antioxidants, Placebo; Dietary Supplement
Lead sponsor: ScienceBased Health; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Glaucoma and Ocular Hypertension
Interventions: DE-117, 0.0015% tafluprost, DE-117 and 0.0015% tafluprost, Placebo; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 10
States / cities: Newport Beach, California • Deerfield Beach, Florida • Largo, Florida + 7 more

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: DE-112, DE-112 Vehicle Solution, Timolol Maleate Solution; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Austin, Texas • San Antonio, Texas

Conditions: Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions: Trabodenoson, Latanoprost, Timolol; Drug
Lead sponsor: Inotek Pharmaceuticals Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Bristol, Tennessee

Conditions: Ocular Hypertension, Primary Open Angle Glaucoma
Interventions: Latanoprost ophthalmic solution, AKB-9778 4%, Placebo; Drug
Lead sponsor: EyePoint Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 21
States / cities: Inglewood, California • Mission Hills, California • Newport Beach, California + 18 more

Conditions: Primary Open-angle Glaucoma
Interventions: iStent supra, Cataract surgery; Device · Procedure
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 45 Years and older
Enrollment: 505 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Racine, Wisconsin

Conditions: Primary Open-angle Glaucoma, Ocular Hypertension
Interventions: OPA-6566, Placebo, Latanoprost; Drug
Lead sponsor: Kubota Vision Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 9
States / cities: Artesia, California • Glendale, California • Roswell, Georgia + 6 more

Conditions: Primary Open Angle Glaucoma, Myopia
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1995 – 2030
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Ocular Hypertension, Primary Open-Angle Glaucoma
Interventions: AGN-210961 Formulation 1, AGN-210961 Formulation 2, AGN-210961 Formulation 3, AGN-210961 Formulation 4, AGN-210961 Formulation 5, AGN-210961 Formulation 6, AGN-210961 Formulation 7, bimatoprost ophthalmic solution 0.03%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Glaucoma, Primary Open Angle
Interventions: ELIOS Procedure; Device
Lead sponsor: Elios Vision, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: Glendale, Arizona • Rock Island, Illinois • St Louis, Missouri + 3 more

Conditions: Sleep Apnea, Obstructive, Primary Open-angle Glaucoma
Interventions: SENSIMED Triggerfish®; Device
Lead sponsor: Sensimed AG; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Primary Open Angle Glaucoma
Interventions: Not listed
Lead sponsor: University of Cincinnati; Other
Eligibility: 0 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Primary Open-angle Glaucoma and Ocular Hypertension
Interventions: DE-117 Ophthalmic Solution QD, DE-117 Ophthalmic Solution BID; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 13
States / cities: Los Angeles, California • Danbury, Connecticut • Brooksville, Florida + 10 more

Search by objective public record fields.

Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Postmarket Registry

Open Label Extension of LipoLat-CS202

Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

DSLT for Reducing Medication in Glaucoma

A Prospective Study on the Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in Achieving >20% Intraocular Pressure (IOP) Reduction Without Medications at 6 Months in Naive, Untreated Glaucoma Patients

To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

ATS907 Ph2a Open-Label Dose-ranging Safety and Tolerability in Primary Open Angle Glaucoma (POAG) and Ocular Hypertension (OHT) Subjects

Cataract Surgery in Conjunction With Ab-interno Canaloplasty Compared to Cataract Surgery Only in Patients With Mild to Moderate Primary Open-Angle Glaucoma

Will Listening to Music Make it Easier to Take a Visual Field Test?

Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients

Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

The Effects of an Antioxidant Formulation on Ocular Blood Flow

A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT

Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension

A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma

Multicenter Investigation of the Glaukos® Suprachoroidal Stent Model G3 In Conjunction With Cataract Surgery

Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension

Diagnostic Innovations in Glaucoma Study

Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Safety and Feasibility of the ELIOS System in POAG Patients

IOP Fluctuations in Patients With Sleep Apnea With or Without Primary Open Angle Glaucoma Using Positive Airway Pressure

Results of Ocular Compression and Suture Release in Trabeculectomy and Combined Surgery

Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6